Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research

Published: Wednesday, September 04, 2013
Last Updated: Wednesday, September 04, 2013
Bookmark and Share
Sanguine BioSciences has signed commercial agreements with more than 200 biomedical researchers at academic, biotechnology and pharmaceutical companies.

Ongoing agreements are in place with a wide range of organizations, ranging from startups, such as Inhibrx, to contract research organizations, such as Applied Immunology, and major drug developers, such as Vertex Pharmaceuticals.

Sanguine directly engages patients diagnosed with severe and chronic diseases to collect and de-identify biospecimen, medical history and other data that can be used in biomarker research. Traditional methods are to obtain biospecimen through hospitals, but this process can result in months of delays as the focus for physicians and staff is on diagnosis and treatment, not facilitating research efforts. By engaging patients directly, Sanguine can meet the needs of researchers and offer timely turnaround of biospecimen and medical data with diverse ranges for age, race, disease state, gender and treatments underway. The patient engagement tactics used by the company have led to a 95 percent retention rate, which also allow for follow-up draws for longitudinal studies.

“In a very short amount of time, and with only recently hiring our first few sales executives, our company has established agreements with ten of the largest drug developers in the world and continues to see high demand for our offering,” said Brian Neman, founder and chief executive officer of Sanguine. “Researchers have specific needs to complete studies in early discovery work, sometimes run with blood samples drawn the same day and other times requiring follow-up draws on exact time schedules, but traditional strategies to obtain these add months to the timeline. Our commitment to patient engagement, transparency and advocacy removes much of this wait time – accelerating the research and increasing the efficiency of the process overall.”

Sanguine is able to meet, review disclosures and collect blood samples in a patient’s home with its own phlebotomists in multiple major U.S. cities. Patients are also able to track how their de-identified biospecimen and data are used through the donor web portal. The company is able to collect and process blood from patients with any disease and has already built large libraries in multiple chronic and severe conditions, including Huntington’s disease, rheumatoid arthritis, systemic lupus erythematosus, Crohn’s disease, ulcerative colitis and others.

In order to maintain appropriate confidentiality, all samples are de-identified immediately upon collection. Sanguine maintains and reviews internal ethical guidelines for the procedures under high scrutiny from an independent review board.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos